drugset / Trial / NCT00140374

Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)

NCT00140374 ↗

Phase 1/2 Completed 36 enrolled Cell Genesys
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with GVAX® Vaccine for Prostate Cancer. Clinical observations and laboratory measurements will be monitored to evaluate safety and toxicity. Additionally, the antitumor effects of GVAX® Vaccine for Prostate Cancer on serum PSA levels, will be evaluated and antitumor responses will be quantitated.

Timeline

Start
1998-12
Primary completion
—
Completion
2001-02

Drugs

EvaluationDrugModalityDoseRoute
Subject GVAX Vaccine — —

Indications